Author Panel

Results for: cancer treatment

10 results found in 0.6 seconds
Search Sources
Database
Complete
10 results
PubMed/NCBI
Loading...
0 results
arXiv
Loading...
0 results
Semantic Scholar
Loading...
0 results
CrossRef
Loading...
0 results
2026 murugesan2026medicinal DATABASE
Medicinal Chemistry Perspectives on Molecular Targets and Targeted Therapeutic Strategies in Breast Cancer.

Murugesan, Dhinesh Kumar; Rajagopal, Kalirajan; Shevate, Krishna; Raman, Kannan; M, Nandhini Devi

Mini reviews in medicinal chemistry

Breast cancer is one of the major causes of morbidity and mortality in cancer among women in the global society. The condition is highly heterogeneous and shows significant variation in molecular subtypes, clinical behaviour, and response to treatment. Despite significant progress in early diagnosis and the development of targeted treatment approaches, therapeutic resistance and tumour recurrence remain obstacles to long-term disease control. In this review, the authors provide a detailed discussion of new therapeutic targets in breast cancer and the most important molecular pathways associated with resistance to existing therapies. Hormone receptor-positive, HER2- positive, and triple-negative breast cancer are major subtypes of breast cancer that have different molecular characteristics and therapeutic vulnerabilities. The estrogen receptor alpha remains a key part of endocrine therapy in hormone receptor-positive breast cancer, but acquired resistance often occurs as a result of ESR1 gene mutations and receptor conformational changes. Monoclonal antibodies, antibody drug conjugates, and tyrosine kinase inhibitors, which are HER2-targeted therapies, play a significant role in improving outcomes in HER2-positive tumours, but intrinsic and adaptive resistance remain significant clinical challenges. Immunity checkpoint inhibitors such as atezolizumab are increasingly used in the treatment of triple-negative breast cancer, a cancer type that does not have known hormonal and HER2 targets, especially in tumours that express PD L1. The dysregulation of several important signalling pathways, including PI3K, AKT, mTOR, and CDK4/6, has been observed in most breast cancer subtypes and offers valuable targets for therapeutic intervention, as exemplified recently by the approval of agents like alpelisib and inavolisib. Moreover, androgen receptor signalling, particularly on certain subsets of triple-negative breast cancer, has become another potentially fruitful therapeutic target. The tumour microenvironment is a major component of cancer stem cells, immune cells, and stromal elements that are important for tumour progression and treatment resistance. Crosstalk between cancer stem cells and the tumour microenvironment, mediated by signalling pathways including Wnt, Notch, and Hedgehog, is a promising area of research for developing new therapeutic approaches. Further insight into these molecular targets and resistance pathways is key to developing an individualised, sustainable treatment regimen for breast cancer.
2026 wong2026adolescent DATABASE
Adolescent and Young Adult Cancer Survivors' Perspectives About Experiences of Cancer Care in Central America, the Caribbean, Mexico, and Peru: A Qualitative Study.

Wong, Samantha L; Rossell, Nuria; Johnston, Emily E; Rios, Ligia; García, Wendy Gómez; Morales, Daniel Ortiz; Antillon-Klussmann, Federico; Fu, Ligia; Fuentes-Alabi, Soad; Bobadilla, Ligia; Rodriguez-Loza, Carolina; Apesoa-Varano, Ester Carolina; Lopez, Salvador Arechiga; Malogolowkin, Marcio; Friedrich, Paola; Alvarez, Elysia

JCO global oncology , 12 : e2500410

There is a significant gap in treatment outcomes and services for the adolescent and young adult (AYA, age 15-39 years) cancer population globally. Improving outcomes requires active participation from health care professionals, policymakers, and patients. In Latin America (LATAM), little is known about the treatment experiences of AYAs diagnosed with cancer. Their perspectives are crucial for developing a comprehensive approach to AYA cancer care in this region. Therefore, we sought to explore the treatment experiences of AYA cancer survivors in LATAM and identify key areas for improving cancer care. This qualitative, exploratory study used convenience sampling to conduct semistructured focus group discussions (FGDs). Between August 2022 and May 2023, FGDs were conducted over Zoom with participants from Peru, Mexico, the Dominican Republic, Guatemala, Costa Rica, Honduras, and El Salvador. Participants were asked to share their thoughts and experiences regarding their diagnosis, treatment process, information received during and after treatment, types of facilities, available services and staff, and their primary needs throughout treatment. We identified common themes in the AYA cancer care experience in these through inductive analysis, along with recommendations for improvement. Twenty-four survivors (16 female and eight male) participated in eight focus groups. Six themes emerged: access to treatment, diagnosis and information disclosure, being an AYA during treatment, the illness experience, post-treatment challenges, and recommendations for care. Key issues included inadequate information about diagnosis and treatment, emotional distress from disrupted schooling, lack of regular psychological support, limited interaction with peers during treatment, and feeling unprepared for life after treatment. The findings underscore the need for improved communication and empathy from doctors, enhanced psychosocial support, better provision of information throughout treatment, and facilitated contact with fellow survivors to improve care for this unique patient population.
2026 breivik2026framing DATABASE
Framing analysis as a pedagogical tool for broadening medical students' understanding of cancer: a course evaluation.

Breivik, Jarle; Lie, Hanne Cathrine

BMC medical education

Cancer is a complex phenomenon encompassing a range of cultural and biomedical dimensions. Traditional medical curricula often fail to reflect this complexity, highlighting the need for interdisciplinary approaches that help medical students develop a more integrated understanding of disease by connecting diverse knowledge, patient perspectives, and societal contexts. This study evaluates how framing analysis-a method from communication studies-can be used as a pedagogical tool to broaden medical students' understanding and critical thinking about complex health issues, using cancer as a key example. We conducted a course evaluation of a two-week elective titled "Cancer Communication" within the University of Oslo's medical program, offered annually to approximately 20 third-year students. Working in teams, students explored research questions related to cancer communication through lectures, workshops, guided research, and excursions. They learned framing analysis by applying a published tool for examining public cancer discourse. Anonymous pre-course free associations and post-course reflections were analyzed thematically to identify changes in students' understanding of cancer during the course. Students' team presentations, orally evaluated as part of the final course examination, supported our assessment of how students applied framing analysis to cancer-related communication topics. Students' initial responses reflected relatively simple and emotionally charged associations with cancer, often centered on fear, death, treatment burden, and familiar cancer stereotypes. Their post-course reflections suggested increased media literacy, critical thinking, and the ability to integrate multiple narratives about cancer. In their final presentations, students applied framing analysis to critically evaluate media portrayals and reflect on how different framings shape public and professional perceptions of disease. The post-course reflections further suggested greater empathy for cancer patients and an increased awareness of social and cultural influences on medical practice. Integrating framing analysis into medical education appeared to broaden students' understanding of cancer as a multidimensional phenomenon, supporting reflective and interdisciplinary thinking and encouraging them to move beyond traditional biomedical perspectives. These findings suggest that framing analysis and similar communication-based approaches may serve as useful pedagogical tools in health professions education to enhance critical reflection.
2025 2025the DATABASE
The global, regional, and national burden of cancer, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023.

Lancet (London, England) , 406 : 1565-1586

Cancer is a leading cause of death globally. Accurate cancer burden information is crucial for policy planning, but many countries do not have up-to-date cancer surveillance data. To inform global cancer-control efforts, we used the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023 framework to generate and analyse estimates of cancer burden for 47 cancer types or groupings by age, sex, and 204 countries and territories from 1990 to 2023, cancer burden attributable to selected risk factors from 1990 to 2023, and forecasted cancer burden up to 2050. Cancer estimation in GBD 2023 used data from population-based cancer registration systems, vital registration systems, and verbal autopsies. Cancer mortality was estimated using ensemble models, with incidence informed by mortality estimates and mortality-to-incidence ratios (MIRs). Prevalence estimates were generated from modelled survival estimates, then multiplied by disability weights to estimate years lived with disability (YLDs). Years of life lost (YLLs) were estimated by multiplying age-specific cancer deaths by the GBD standard life expectancy at the age of death. Disability-adjusted life-years (DALYs) were calculated as the sum of YLLs and YLDs. We used the GBD 2023 comparative risk assessment framework to estimate cancer burden attributable to 44 behavioural, environmental and occupational, and metabolic risk factors. To forecast cancer burden from 2024 to 2050, we used the GBD 2023 forecasting framework, which included forecasts of relevant risk factor exposures and used Socio-demographic Index as a covariate for forecasting the proportion of each cancer not affected by these risk factors. Progress towards the UN Sustainable Development Goal (SDG) target 3.4 aim to reduce non-communicable disease mortality by a third between 2015 and 2030 was estimated for cancer. In 2023, excluding non-melanoma skin cancers, there were 18·5 million (95% uncertainty interval 16·4 to 20·7) incident cases of cancer and 10·4 million (9·65 to 10·9) deaths, contributing to 271 million (255 to 285) DALYs globally. Of these, 57·9% (56·1 to 59·8) of incident cases and 65·8% (64·3 to 67·6) of cancer deaths occurred in low-income to upper-middle-income countries based on World Bank income group classifications. Cancer was the second leading cause of deaths globally in 2023 after cardiovascular diseases. There were 4·33 million (3·85 to 4·78) risk-attributable cancer deaths globally in 2023, comprising 41·7% (37·8 to 45·4) of all cancer deaths. Risk-attributable cancer deaths increased by 72·3% (57·1 to 86·8) from 1990 to 2023, whereas overall global cancer deaths increased by 74·3% (62·2 to 86·2) over the same period. The reference forecasts (the most likely future) estimate that in 2050 there will be 30·5 million (22·9 to 38·9) cases and 18·6 million (15·6 to 21·5) deaths from cancer globally, 60·7% (41·9 to 80·6) and 74·5% (50·1 to 104·2) increases from 2024, respectively. These forecasted increases in deaths are greater in low-income and middle-income countries (90·6% [61·0 to 127·0]) compared with high-income countries (42·8% [28·3 to 58·6]). Most of these increases are likely due to demographic changes, as age-standardised death rates are forecast to change by -5·6% (-12·8 to 4·6) between 2024 and 2050 globally. Between 2015 and 2030, the probability of dying due to cancer between the ages of 30 years and 70 years was forecasted to have a relative decrease of 6·5% (3·2 to 10·3). Cancer is a major contributor to global disease burden, with increasing numbers of cases and deaths forecasted up to 2050 and a disproportionate growth in burden in countries with scarce resources. The decline in age-standardised mortality rates from cancer is encouraging but insufficient to meet the SDG target set for 2030. Effectively and sustainably addressing cancer burden globally will require comprehensive national and international efforts that consider health systems and context in the development and implementation of cancer-control strategies across the continuum of prevention, diagnosis, and treatment. Gates Foundation, St Jude Children's Research Hospital, and St Baldrick's Foundation.
2025 wagle2025cancer DATABASE
Cancer treatment and survivorship statistics, 2025

N. S. Wagle; Leticia M. Nogueira; Theresa P Devasia; A. Mariotto; K. R. Yabroff; Farhad Islami; A. Jemal; Rick Alteri; Patricia A. Ganz; R. Siegel

Ca

The number of people living with a history of cancer in the United States continues to rise because of the growth and aging of the population as well as improved survival through advances in early detection and treatment. To assist the public health community serve the needs of these survivors, the American Cancer Society and the National Cancer Institute collaborate triennially to estimate cancer prevalence in the United States using data from the Surveillance, Epidemiology, and End Results cancer registries, the Centers for Disease Control and Prevention's National Center for Health Statistics, and the United States Census Bureau. In addition, cancer treatment patterns are presented from the National Cancer Database along with a brief overview of treatment‐related side effects. As of January 1, 2025, about 18.6 million people were living in the United States with a history of cancer, and this number is projected to exceed 22 million by 2035. The three most prevalent cancers are prostate (3,552,460), melanoma of the skin (816,580), and colorectum (729,550) among males and breast (4,305,570), uterine corpus (945,540), and thyroid (859,890) among females. About one half (51%) of survivors were diagnosed within the past 10 years, and nearly four fifths (79%) were aged 60 years and older. Racial differences in treatment in 2021 were common across disease stage; for example, Black people with stage I‐II lung cancer were less likely to undergo surgery than their White counterparts (47% vs. 52%). Larger disparities exist for rectal cancer, for which 39% of Black people with stage I disease undergo proctectomy or proctocolectomy compared to 64% of their White counterparts. Targeted, multi‐level efforts to expand access to high‐quality care and survivorship resources are vital to reducing disparities and advancing support for all survivors of cancer.
2023 chavda2023advanced DATABASE
Advanced Phytochemical-Based Nanocarrier Systems for the Treatment of Breast Cancer

Vivek P. Chavda; Lakshmi Vineela Nalla; Pankti C. Balar; Rajashri Bezbaruah; V. Apostolopoulos; Rajeev K. Singla; A. Khadela; Lalitkumar K. Vora; V. Uversky

Cancers

Simple Summary Breast cancer is a concern for the healthcare system. Even with the advancement of science and technology, the current system for therapeutics and diagnostics seems to have numerous pitfalls. Phytochemical-mediated nanocarriers come into the picture to outrange the drawbacks of the conventional breast cancer management method. Phytochemicals have been a useful tool since time immemorial, and developing a sophisticated fusion of these chemicals with nanocarrier enhanced its effectiveness. This ensures targeted, time-controlled drug delivery. This article emphasizes the development of phytochemical-based nanocarriers corresponding to breast cancer. Moreover, the article presents the unhighlighted parts of the therapeutical industry to help patients. Enhancing patients’ quality of life would uplift the healthcare system. Abstract As the world’s most prevalent cancer, breast cancer imposes a significant societal health burden and is among the leading causes of cancer death in women worldwide. Despite the notable improvements in survival in countries with early detection programs, combined with different modes of treatment to eradicate invasive disease, the current chemotherapy regimen faces significant challenges associated with chemotherapy-induced side effects and the development of drug resistance. Therefore, serious concerns regarding current chemotherapeutics are pressuring researchers to develop alternative therapeutics with better efficacy and safety. Due to their extremely biocompatible nature and efficient destruction of cancer cells via numerous mechanisms, phytochemicals have emerged as one of the attractive alternative therapies for chemotherapeutics to treat breast cancer. Additionally, phytofabricated nanocarriers, whether used alone or in conjunction with other loaded phytotherapeutics or chemotherapeutics, showed promising results in treating breast cancer. In the current review, we emphasize the anticancer activity of phytochemical-instigated nanocarriers and phytochemical-loaded nanocarriers against breast cancer both in vitro and in vivo. Since diverse mechanisms are implicated in the anticancer activity of phytochemicals, a strong emphasis is placed on the anticancer pathways underlying their action. Furthermore, we discuss the selective targeted delivery of phytofabricated nanocarriers to cancer cells and consider research gaps, recent developments, and the druggability of phytoceuticals. Combining phytochemical and chemotherapeutic agents with nanotechnology might have far-reaching impacts in the future.
2022 miller2022cancer DATABASE
Cancer treatment and survivorship statistics, 2022

K. Miller; Leticia M. Nogueira; Theresa P Devasia; A. Mariotto; K. R. Yabroff; A. Jemal; J. Kramer; R. Siegel

Ca

The number of cancer survivors continues to increase in the United States due to the growth and aging of the population as well as advances in early detection and treatment. To assist the public health community in better serving these individuals, the American Cancer Society and the National Cancer Institute collaborate triennially to estimate cancer prevalence in the United States using incidence and survival data from the Surveillance, Epidemiology, and End Results cancer registries, vital statistics from the Centers for Disease Control and Prevention’s National Center for Health Statistics, and population projections from the US Census Bureau. Current treatment patterns based on information in the National Cancer Database are presented for the most prevalent cancer types by race, and cancer‐related and treatment‐related side‐effects are also briefly described. More than 18 million Americans (8.3 million males and 9.7 million females) with a history of cancer were alive on January 1, 2022. The 3 most prevalent cancers are prostate (3,523,230), melanoma of the skin (760,640), and colon and rectum (726,450) among males and breast (4,055,770), uterine corpus (891,560), and thyroid (823,800) among females. More than one‐half (53%) of survivors were diagnosed within the past 10 years, and two‐thirds (67%) were aged 65 years or older. One of the largest racial disparities in treatment is for rectal cancer, for which 41% of Black patients with stage I disease receive proctectomy or proctocolectomy compared to 66% of White patients. Surgical receipt is also substantially lower among Black patients with non‐small cell lung cancer, 49% for stages I‐II and 16% for stage III versus 55% and 22% for White patients, respectively. These treatment disparities are exacerbated by the fact that Black patients continue to be less likely to be diagnosed with stage I disease than White patients for most cancers, with some of the largest disparities for female breast (53% vs 68%) and endometrial (59% vs 73%). Although there are a growing number of tools that can assist patients, caregivers, and clinicians in navigating the various phases of cancer survivorship, further evidence‐based strategies and equitable access to available resources are needed to mitigate disparities for communities of color and optimize care for people with a history of cancer. CA Cancer J Clin. 2022;72:409‐436.
2019 waks2019breast DATABASE
Breast Cancer Treatment: A Review

Adrienne G. Waks; E. Winer

Journal of the American Medical Association (JAMA)

Importance Breast cancer will be diagnosed in 12% of women in the United States over the course of their lifetimes and more than 250 000 new cases of breast cancer were diagnosed in the United States in 2017. This review focuses on current approaches and evolving strategies for local and systemic therapy of breast cancer. Observations Breast cancer is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). More than 90% of breast cancers are not metastatic at the time of diagnosis. For people presenting without metastatic disease, therapeutic goals are tumor eradication and preventing recurrence. Triple-negative breast cancer is more likely to recur than the other 2 subtypes, with 85% 5-year breast cancer–specific survival for stage I triple-negative tumors vs 94% to 99% for hormone receptor positive and ERBB2 positive. Systemic therapy for nonmetastatic breast cancer is determined by subtype: patients with hormone receptor–positive tumors receive endocrine therapy, and a minority receive chemotherapy as well; patients with ERBB2-positive tumors receive ERBB2-targeted antibody or small-molecule inhibitor therapy combined with chemotherapy; and patients with triple-negative tumors receive chemotherapy alone. Local therapy for all patients with nonmetastatic breast cancer consists of surgical resection, with consideration of postoperative radiation if lumpectomy is performed. Increasingly, some systemic therapy is delivered before surgery. Tailoring postoperative treatment based on preoperative treatment response is under investigation. Metastatic breast cancer is treated according to subtype, with goals of prolonging life and palliating symptoms. Median overall survival for metastatic triple-negative breast cancer is approximately 1 year vs approximately 5 years for the other 2 subtypes. Conclusions and Relevance Breast cancer consists of 3 major tumor subtypes categorized according to estrogen or progesterone receptor expression and ERBB2 gene amplification. The 3 subtypes have distinct risk profiles and treatment strategies. Optimal therapy for each patient depends on tumor subtype, anatomic cancer stage, and patient preferences.
2019 miller2019cancer DATABASE
Cancer treatment and survivorship statistics, 2019

K. Miller; Leticia M. Nogueira; A. Mariotto; J. Rowland; K. R. Yabroff; C. Alfano; A. Jemal; J. Kramer; R. Siegel

Ca

The number of cancer survivors continues to increase in the United States because of the growth and aging of the population as well as advances in early detection and treatment. To assist the public health community in better serving these individuals, the American Cancer Society and the National Cancer Institute collaborate every 3 years to estimate cancer prevalence in the United States using incidence and survival data from the Surveillance, Epidemiology, and End Results cancer registries; vital statistics from the Centers for Disease Control and Prevention's National Center for Health Statistics; and population projections from the US Census Bureau. Current treatment patterns based on information in the National Cancer Data Base are presented for the most prevalent cancer types. Cancer‐related and treatment‐related short‐term, long‐term, and late health effects are also briefly described. More than 16.9 million Americans (8.1 million males and 8.8 million females) with a history of cancer were alive on January 1, 2019; this number is projected to reach more than 22.1 million by January 1, 2030 based on the growth and aging of the population alone. The 3 most prevalent cancers in 2019 are prostate (3,650,030), colon and rectum (776,120), and melanoma of the skin (684,470) among males, and breast (3,861,520), uterine corpus (807,860), and colon and rectum (768,650) among females. More than one‐half (56%) of survivors were diagnosed within the past 10 years, and almost two‐thirds (64%) are aged 65 years or older. People with a history of cancer have unique medical and psychosocial needs that require proactive assessment and management by follow‐up care providers. Although there are growing numbers of tools that can assist patients, caregivers, and clinicians in navigating the various phases of cancer survivorship, further evidence‐based resources are needed to optimize care.
2016 miller2016cancer DATABASE
Cancer treatment and survivorship statistics, 2016

K. Miller; R. Siegel; C. Lin; A. Mariotto; J. Kramer; J. Rowland; K. Stein; Rick Alteri; A. Jemal

Ca

The number of cancer survivors continues to increase because of both advances in early detection and treatment and the aging and growth of the population. For the public health community to better serve these survivors, the American Cancer Society and the National Cancer Institute collaborate to estimate the number of current and future cancer survivors using data from the Surveillance, Epidemiology, and End Results cancer registries. In addition, current treatment patterns for the most prevalent cancer types are presented based on information in the National Cancer Data Base and treatment‐related side effects are briefly described. More than 15.5 million Americans with a history of cancer were alive on January 1, 2016, and this number is projected to reach more than 20 million by January 1, 2026. The 3 most prevalent cancers are prostate (3,306,760), colon and rectum (724,690), and melanoma (614,460) among males and breast (3,560,570), uterine corpus (757,190), and colon and rectum (727,350) among females. More than one‐half (56%) of survivors were diagnosed within the past 10 years, and almost one‐half (47%) are aged 70 years or older. People with a history of cancer have unique medical and psychosocial needs that require proactive assessment and management by primary care providers. Although there are a growing number of tools that can assist patients, caregivers, and clinicians in navigating the various phases of cancer survivorship, further evidence‐based resources are needed to optimize care. CA Cancer J Clin 2016;66:271‐289. © 2016 American Cancer Society